Clinical Overview of CJC 1295 in Body Composition Management

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

CJC 1295 is a synthetic analog derived from growth hormone–releasing hormone (GHRH). It incorporates the first 29 amino acids of native GHRH with the addition of a drug affinity complex (DAC), which substantially extends its half-life. This structural modification enhances stability and solubility, allowing for more sustained physiological effects compared to endogenous GHRH.

Mechanism of Action

CJC 1295 functions as a full agonist at the GHRH receptor, stimulating the anterior pituitary to release growth hormone (GH). Preclinical studies in murine models have demonstrated a two- to ten-fold increase in GH concentrations following administration. Due to its prolonged half-life, the biological activity of CJC 1295 can extend for several days after a single dose.

Physiological Effects

Elevated GH secretion through CJC 1295 administration has been associated with multiple physiological benefits in experimental settings, including:

• Promotion of skeletal muscle hypertrophy
• Stimulation of linear bone growth
• Enhanced lipid metabolism
• Improved tissue repair and recovery
• Increased depth and duration of slow-wave sleep
• Positive effects on cognitive performance

Impact on Body Composition

Research in genetically modified animal models lacking functional GHRH expression has shown that CJC 1295 can restore normal body weight and body composition. Importantly, these effects were achieved at lower dosages compared to GHRH alone, suggesting superior potency. Treated subjects demonstrated normalized weight, while untreated controls developed obesity. These findings support the potential of CJC 1295 in modulating fat reduction and muscle preservation.

Metabolic Considerations

Skeletal muscle is a primary determinant of basal metabolic rate. By augmenting lean body mass, CJC 1295 indirectly elevates caloric expenditure at rest. This increases the threshold for fat accumulation while promoting fat utilization. The net effect is a metabolic environment that favors energy consumption over storage, facilitating improvements in body composition.

Additional Clinical Observations

Beyond its role in metabolism and body composition, enhanced GH secretion through CJC 1295 has been correlated with:

• Improved cardiovascular parameters
• Enhanced neurocognitive function and memory consolidation
• Acceleration of tendon and skin healing processes
• Positive influence on reproductive health in specific contexts

Notably, unlike certain GH secretagogues that disrupt natural pulsatile GH secretion, CJC 1295 appears to preserve physiologic release patterns while increasing overall hormone output. This feature may reduce adverse outcomes such as disproportionate bone growth.

Distinction Between CJC 1295 and Modified GRF (1-29)

Terminological confusion often arises between CJC 1295 and its variant forms. In strict terms, CJC 1295 includes the DAC modification, whereas the unmodified sequence of the first 29 amino acids of GHRH is more accurately referred to as Modified GRF (1-29). The DAC extension increases the peptide’s half-life from minutes to nearly 24 hours, allowing for more consistent hormonal stimulation compared with rapid, short-lived GHRH analogues.

Clinical Summary

CJC 1295 demonstrates significant potential as a growth hormone–releasing therapy with implications for fat reduction, muscle development, and recovery processes. Its prolonged activity and ability to maintain pulsatile GH release distinguish it from other secretagogues. Ongoing investigations are assessing its synergistic use with growth hormone secretagogue receptor agonists, such as ipamorelin, which may further amplify GH release through complementary mechanisms.

REFERENCES

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
2. Volpe, A., Coukos, G., Barreca, A., Giordano, G., Artini, P. G., & Genazzani, A. R. (1991). Clinical use of growth hormone-releasing factor for induction of superovulation. Human reproduction (Oxford, England), 6(9), 1228–1232. https://doi.org/10.1093/oxfordjournals.humrep.a137517
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
4. Veldhuis JD, Iranmanesh A, Lizarralde G, Johnson ML. Amplitude modulation of a burstlike mode of growth hormone secretion subserves the sexual dimorphism of circulating GH concentrations in man. J Clin Invest. 1989;84(5):1286–94.
5. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002;13(8):299–303.

Product available for research use only: